D. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00

Key Points

• D. Boral Capital has increased its price target for Invivyd (NASDAQ:IVVD) from $1.00 to $2.00, indicating a potential upside of 40.35%.
• Currently, Invivyd has received mixed ratings from analysts, with one Strong Buy, four Buy ratings, and one Sell rating, leading to an average target price of $5.14.
• Invivyd reported a loss of ($0.12) earnings per share for the last quarter, falling short of analysts' expectations of ($0.04).

Invivyd (NASDAQ:IVVD - Get Free Report) had its price target boosted by equities researchers at D. Boral Capital from $1.00 to $2.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. D. Boral Capital's target price indicates a potential upside of 40.35% from the company's previous close.

IVVD has been the topic of a number of other research reports. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Invivyd in a research report on Wednesday, August 27th. Cantor Fitzgerald started coverage on shares of Invivyd in a research report on Monday. They set an "overweight" rating and a $10.00 price target on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Invivyd in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $5.14.

Invivyd Stock Performance

IVVD traded up $0.27 on Monday, reaching $1.43. The company had a trading volume of 11,139,379 shares, compared to its average volume of 7,512,821. The stock has a market cap of $171.20 million, a P/E ratio of -1.55 and a beta of 0.57. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $2.74. The company's fifty day moving average is $0.96 and its 200 day moving average is $0.79.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. On average, sell-side analysts expect that Invivyd will post -1.64 EPS for the current year.

Insider Activity

In other Invivyd news, insider Jill Andersen sold 49,402 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total transaction of $28,159.14. Following the completion of the transaction, the insider directly owned 84,446 shares of the company's stock, valued at approximately $48,134.22. This represents a 36.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 277,654 shares of company stock worth $167,215. Company insiders own 25.40% of the company's stock.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd purchased a new position in Invivyd during the 2nd quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC grew its stake in Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after acquiring an additional 28,146 shares in the last quarter. Nuveen LLC bought a new stake in Invivyd during the 1st quarter worth approximately $65,000. Invesco Ltd. increased its holdings in Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company's stock worth $66,000 after acquiring an additional 71,485 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Invivyd in the 1st quarter worth approximately $66,000. Institutional investors own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.